Successful Switching to Adalimumab in an Infliximab-allergic Patient with Severe Behçet Disease-related Uveitis

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2009 Oct 10

PMID 19816689

Citations 21

Authors

Kaoru Takase

Shigeru Ohno

Haruko Ideguchi

Eiichi Uchio

Mitsuhiro Takeno

Yoshiaki Ishigatsubo

Affiliations

Soon will be listed here.

Abstract

Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behçet's disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. We here report successful switching from infliximab to adalimumab in a BD patient. Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to cyclosporine until the patient had experienced repeated infliximab-related infusion reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.

Citing Articles

Monoclonal Antibodies for the Treatment of Ocular Diseases.

Henriques C, da Ana R, Krambeck K, Miguel S, Santini A, Zielinska A J Clin Med. 2024; 13(19).

PMID: 39407875 PMC: 11482488. DOI: 10.3390/jcm13195815.

Decoding Behcet's Uveitis: an In-depth review of pathogenesis and therapeutic advances.

Guan Y, Li F, Li N, Yang P J Neuroinflammation. 2024; 21(1):133.

PMID: 38778397 PMC: 11112928. DOI: 10.1186/s12974-024-03123-6.

Comparative results of use and switching of anti-TNF-alpha agents in adult Behçet's uveitis.

Mesen S, Ozer M, Batur M Indian J Ophthalmol. 2024; 72(Suppl 3):S521-S528.

PMID: 38317320 PMC: 467025. DOI: 10.4103/IJO.IJO_2011_23.

Shaping the Future of Behçet's Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies.

Li B, Li H, Huang Q, Zheng Y Ophthalmol Ther. 2023; 12(5):2295-2321.

PMID: 37477857 PMC: 10442050. DOI: 10.1007/s40123-023-00767-0.

Treatment of non-infectious retinal vasculitis.

Rivera P, Gupta A, Kombo N Ther Adv Ophthalmol. 2023; 15:25158414231152761.

PMID: 37077655 PMC: 10107051. DOI: 10.1177/25158414231152761.

References

Imrie F, Dick A . Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007; 18(6):481-6. DOI: 10.1097/ICU.0b013e3282f03d42. View

Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M . Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004; 31(7):1362-8. View

Oussalah A, Babouri A, Chevaux J, Stancu L, Trouilloud I, Bensenane M . Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther. 2008; 29(4):416-23. DOI: 10.1111/j.1365-2036.2008.03902.x. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Sfikakis P . Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002; 61 Suppl 2:ii51-3. PMC: 1766720. DOI: 10.1136/ard.61.suppl_2.ii51. View

Theodossiadis P, Markomichelakis N, Sfikakis P . Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007; 27(4):399-413. DOI: 10.1097/MAJ.0b013e3180318fbc. View

Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M . Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum. 2005; 52(8):2478-84. DOI: 10.1002/art.21231. View

Hale S, Lightman S . Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine. 2006; 33(4):231-7. DOI: 10.1016/j.cyto.2005.12.012. View

Sfikakis P, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A . Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford). 2007; 46(5):736-41. DOI: 10.1093/rheumatology/kem034. View

10.

van Laar J, Missotten T, van Daele P, Jamnitski A, Baarsma G, van Hagen P . Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis. 2006; 66(4):565-6. PMC: 1856047. DOI: 10.1136/ard.2006.064279. View

11.

Papadakis K, Shaye O, Vasiliauskas E, Ippoliti A, Dubinsky M, Birt J . Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005; 100(1):75-9. DOI: 10.1111/j.1572-0241.2005.40647.x. View

12.

Mushtaq B, Saeed T, Situnayake R, Murray P . Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond). 2006; 21(6):824-5. DOI: 10.1038/sj.eye.6702352. View

13.

Sfikakis P, Theodossiadis P, Katsiari C, Kaklamanis P, Markomichelakis N . Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001; 358(9278):295-6. DOI: 10.1016/s0140-6736(01)05497-6. View

14.

Sands B, Blank M, Patel K, van Deventer S . Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004; 2(10):912-20. DOI: 10.1016/s1542-3565(04)00414-8. View